CD80 Protein (CD80)

Catalog No. ABIN7194953

Recombinant CD80 protein expressed in HEK-293 Cells.

Quick Overview for CD80 Protein (CD80) (ABIN7194953)

Target: CD80

Protein Type: Recombinant

Origin: Human

Source: HEK-293 Cells

Purity: > 85 % as determined by reducing SDS-PAGE.

Product Details

Purpose: Recombinant Human CD80/B7-1 Protein

Sequence: Met 1-Asn 242

Characteristics: The mature form of human B7-1 (NP_005182.1) extracellular domain (Met 1-Asn 242) with five amini acids (DDDDK) at the C-terminus was expressed and purified.

Sterility: 0.2 μm filtered

Endotoxin Level: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Not validated for activity

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween 80 are added as protectants before lyophilization.

Storage: 4 °C,-20 °C,-80 °C

Storage Comment: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Expiry Date: 12 months

Target Details

Target: CD80

Alternative Name: CD80/B7-1

Background: Activation B7-1 antigen,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,CD28LGB7-1 antigen,CD80,LAB7,T-lymphocyte activation antigen CD80,The B-lymphocyte activation antigen B7-1 (referred to as B7), also known as CD80, is a member of cell surface immunoglobulin superfamily and is expressed on the surface of antigen-presenting cells including activated B cells, macrophages and dendritic cells. As costimulatory ligands, B7-1 which exists predominantly as dimer and the related protein B7-2, interact with the costimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus constitute one of the dominant pathways that regulate T cell activation and tolerance, cytokine production, and the generation of CTL. The B7/CD28/CTLA4 pathway has the ability to both positively and negatively regulate immune responses. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

Molecular Weight: 25.5 kDa

Gene ID: 941

NCBI Accession: NP_005182

UniProt: P33681

Pathways: TCR Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints